AU2007283404B2 - Thiophenecarboxamide derivatives as EP4 receptor ligands - Google Patents

Thiophenecarboxamide derivatives as EP4 receptor ligands Download PDF

Info

Publication number
AU2007283404B2
AU2007283404B2 AU2007283404A AU2007283404A AU2007283404B2 AU 2007283404 B2 AU2007283404 B2 AU 2007283404B2 AU 2007283404 A AU2007283404 A AU 2007283404A AU 2007283404 A AU2007283404 A AU 2007283404A AU 2007283404 B2 AU2007283404 B2 AU 2007283404B2
Authority
AU
Australia
Prior art keywords
group
pct
compound according
formula
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007283404A
Other languages
English (en)
Other versions
AU2007283404A1 (en
Inventor
Marc Blouin
Jason Burch
Christophe Mellon
Han Yongxin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of AU2007283404A1 publication Critical patent/AU2007283404A1/en
Application granted granted Critical
Publication of AU2007283404B2 publication Critical patent/AU2007283404B2/en
Assigned to MERCK CANADA INC. reassignment MERCK CANADA INC. Amend patent request/document other than specification (104) Assignors: MERCK FROSST CANADA LTD.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU2007283404A 2006-08-11 2007-08-10 Thiophenecarboxamide derivatives as EP4 receptor ligands Ceased AU2007283404B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83725206P 2006-08-11 2006-08-11
US60/837,252 2006-08-11
PCT/CA2007/001404 WO2008017164A1 (en) 2006-08-11 2007-08-10 Thiophenecarboxamide derivatives as ep4 receptor ligands

Publications (2)

Publication Number Publication Date
AU2007283404A1 AU2007283404A1 (en) 2008-02-14
AU2007283404B2 true AU2007283404B2 (en) 2013-04-18

Family

ID=39032586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007283404A Ceased AU2007283404B2 (en) 2006-08-11 2007-08-10 Thiophenecarboxamide derivatives as EP4 receptor ligands

Country Status (8)

Country Link
US (1) US8969394B2 (enExample)
EP (1) EP2054401B1 (enExample)
JP (1) JP5259592B2 (enExample)
CN (1) CN101541778B (enExample)
AU (1) AU2007283404B2 (enExample)
CA (1) CA2660133C (enExample)
ES (1) ES2421453T3 (enExample)
WO (1) WO2008017164A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028463A1 (en) * 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
CA2694347A1 (en) * 2007-08-09 2009-02-12 Merck Sharp & Dohme Corp. Process for making thiophene carboxamide derivative
SI2565191T1 (sl) * 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
EP2320906B1 (en) * 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
JP2013508282A (ja) 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
MX341482B (es) * 2010-02-22 2016-08-22 Raqualia Pharma Inc Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
PH12013500467A1 (en) 2010-09-21 2013-04-29 Eisai R&D Man Co Ltd Pharmaceutical composition
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
KR102556734B1 (ko) 2013-03-19 2023-07-18 에스크엣 인크. 연골질환 치료에서의 ep4 수용체 길항제의 용도
PT3009426T (pt) 2013-06-12 2018-06-08 Kaken Pharma Co Ltd Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US20170182003A1 (en) * 2014-05-23 2017-06-29 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
US9926262B2 (en) * 2014-06-06 2018-03-27 Allergan, Inc. EP4 agonists as therapeutic compounds
CN105037186A (zh) * 2015-06-17 2015-11-11 苏州敬业医药化工有限公司 一种氨甲苯酸的制备方法
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
US20200069686A1 (en) 2017-05-18 2020-03-05 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
US10202415B1 (en) 2017-10-19 2019-02-12 King Saud University Method of synthesizing of 3-oxolupenal nanoparticles
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN112552200B (zh) * 2019-09-10 2024-03-12 烟台药物研究所 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法
US20240002388A1 (en) * 2020-08-18 2024-01-04 Hutchison Medipharma Limited Pyrimidinone compounds and uses thereof
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0752421B1 (en) 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
BR0116850A (pt) * 2001-01-31 2004-02-25 Pfizer Prod Inc Derivados de amida de ácido tiazolil-, oxazolil-, pirrolil- e imidazolil- úteis como inibidores de isoenzimas de pde4
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CA2563356A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
JP4054368B2 (ja) * 2004-05-04 2008-02-27 ファイザー株式会社 置換メチルアリール又はヘテロアリールアミド化合物
CN1950334A (zh) * 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
WO2005116010A1 (en) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists

Also Published As

Publication number Publication date
CN101541778B (zh) 2014-10-08
US20090247596A1 (en) 2009-10-01
WO2008017164A1 (en) 2008-02-14
ES2421453T3 (es) 2013-09-02
CA2660133A1 (en) 2008-02-14
AU2007283404A1 (en) 2008-02-14
JP5259592B2 (ja) 2013-08-07
JP2010500293A (ja) 2010-01-07
CA2660133C (en) 2015-10-27
EP2054401A1 (en) 2009-05-06
EP2054401B1 (en) 2013-05-01
CN101541778A (zh) 2009-09-23
EP2054401A4 (en) 2010-10-13
US8969394B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
AU2007283404B2 (en) Thiophenecarboxamide derivatives as EP4 receptor ligands
CA2679175C (en) Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
US7705035B2 (en) Indoline amide derivatives as EP4 receptor ligands
US20090253756A1 (en) Indole Amide Derivatives as EP4 Receptor Antagonists
AU2008232265B2 (en) Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
US8013159B2 (en) Quinoline derivatives as EP4 antagonists
JPH10298180A (ja) ドーパミン受容体拮抗作用を有する化合物
AU2011205048B2 (en) Compounds and methods for the treatment or prevention of flavivirus infections
MXPA00007808A (en) Bicyclic pyrrole derivatives as mcp-1 inhibitors
HK1162301A (en) Heterocyclic amide derivatives as ep4 receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired